For the past 20 years, the world has witnessed remarkable advances in the field of spondyloarthritis (SpA) from better understanding of the genetics and pathophysiology of SpA, utilisation of magnetic resonance imaging (MRI) for early diagnosis, to the discovery of advanced therapeutics for patients with non-steroidal anti-inflammatory drugs (NSAID)-refractory SpA. This is a vast improvement from the past where treatment was limited to NSAIDs and was frequently unsatisfactory for both physician and patient, and where diagnosis was made based on clinical evaluation and structural changes on plain radiographs. These advances have inevitably revolutionised the management of SpA in Singapore and patients can now look forward to an earlier diagnosis of their condition and better treatment. This review summarises the key advances in the field of SpA and describes the aims of the SpA clinic in the Singapore General Hospital (SGH).
GENEtICS
One key advancement in SpA is the identification of new gene associations through genome-wide association studies (GWAS), with discoveries of non-HLA-B27 major histocompatibility complex (MHC) and non-MHC genes contributing to disease susceptibility. A genome-wide association study is defined as any study of genetic variation across the entire human genome that is designed to identify genetic associations with observable traits or the presence or absence of a disease or condition. While HLA-B27 remains the main disease-causing gene in AS, new findings of endoplasmic reticulum aminopeptidase-1 (ERAP-1) and interleukin-23 receptor (IL-23R) gene polymorphisms were found to be associated with AS in a non-synonymous single nucleotide polymorphism association study 10 , and this has been replicated in several studies across different populations in Europe and in Han Chinese [11] [12] [13] .
The new discoveries have translated into increased understanding of the immunological pathways involved in AS, for example, ERAP-1 is known for its role in antigen presentation as a member of the MHC class I presentation pathway while IL-23R is associated with the pathogenic T-helper 17 (Th17) cell pathway 7 . Th17 cell is an important player in the pathogenesis through cytokines such as IL-17A, IL-17F, IL-22, IL-26, TNFα, and GM-CSF and this discovery has led to additional targets for the treatment of SpA 14 . Clinical trials with monoclonal antibodies targeting IL-17A is currently ongoing.
The population attributable risk fraction of HLA-B27, ERAP-1, and IL-23R is 90%, 26%, and 9% respectively, making ERAP-1 the strongest non-MHC gene associated with AS 10 . Carriers of ERAP-1 and IL-23R genes have a 30-40% increased risk of developing AS. ERAP-1 is associated with AS only in HLA-B27 positive patients 15 and in psoriasis patients who are carriers of HLA-Cw6 16 , while IL-23R variants were found to be associated with inflammatory bowel disease 17 and psoriasis 18 . This suggests common genetic risks linking AS and extra-articular manifestations. Other non-MHC related genes found on GWAS were the gene deserts 2p15 and 21q22, but their significance remained unclear 19 .
There has been significant progress in the understanding of HLA-B27 and its involvement in the pathophysiology of SpA. This gene was first identified in 1973 to be associated with human arthropathy 20 and remains one of the strongest genetic associations with any common human disease. This gene is present in about 90% of AS patients and in up to 50% of patients with other types of SpA. AS is a heritable disease, with siblings of probands with AS having >50 times risk of developing the condition compared with individuals in the general population 21 . While it is known that approximately 20% of HLA-B27 positive relatives of AS patients develop SpA 22 , only 1-5% of HLA-B27-positive individuals in the general population develop AS 23 , suggesting that other genes may be involved.
The role of HLA-B27 in the pathogenesis of AS remains unclear but one of the earliest postulations included the "arthritogenic peptide" hypothesis whereby microbial peptides that exhibit molecular mimicry with self-peptides were displayed resulting in an immune response 24 . Another hypothesis is the propensity of B27 to mis-fold, triggering stress responses within the cell and pro-inflammatory cytokines, and its capacity to form covalent heavy chain homodimers amenable to recognition by leukocyte receptors. Current understanding on the functioning of ERAP-1, however, did not favour any one particular HLA-B27-related hypothesis 25 .
The strength of association varies depending on the subtypes of the HLA-B27 and there are now more than 90 subtypes of HLA-B*27 26 . Studies have shown that Singaporeans/Eastern Asians have the B*2704 and B*2705 as the primary subtypes 27, 28 while white Caucasians have HLA-B*2705 and B*2702 as the primary subtypes 29 . While HLA-B*2702, B*2704, and B*2705 are strongly associated with AS, the subtypes B*2706 and B*2709 found in South East Asians (Thailand, Malaysia, and Indonesia) and Sardinia, Italy, respectively, were thought to be protective against AS 26, [30] [31] [32] . Recent reports, however, showed that it is not absolutely protective [33] [34] [35] .
Despite being a major genetic risk for the development of SpA, HLA-B27 is negative in up to 10% of AS cohorts. The disease manifestation is essentially similar with no significant differences in disease activity and clinical and radiographic severity 36, 37 . HLA-B27 negative AS is less likely to be familial, has a later disease onset, and is less likely to respond to anti-tumour necrosis factor (TNF) treatment 38, 39 . 
IMAGING AND EARLY DIAGNOSIS OF SpA
The discovery that MRI can be utilised to detect early inflammatory signals in the sacroiliac joints has significantly changed the overall SpA management and therapy. In the past, plain radiographs were commonly performed to detect structural changes such as joint erosion and subchondral-bone sclerosis at the sacroiliac joints or syndesmophytes formation at the spine (Fig. 1 ), but these changes usually signify late phases of the disease and the patient would have suffered a significant amount of pain or even developed spinal deformity for a considerable number of years. The reliance on plain radiographs of the sacroiliac joints was the result of the modified New York criteria for the classification of AS in 1984 40 . In Singapore, the delay averaged about 7.25 years in a study of 38 Singaporean Chinese AS patients 41 , and 6.3 years in a bigger cohort of Singaporeans 42 , fairly consistent with the average delay elsewhere 43 .
MRI detects inflammatory changes in the sacroiliac joints (synovitis within the sacroiliac joint, subchondral bone oedema, and synovial fluid) before structural lesions such as fat deposition, sclerosis, erosions, or bony ankylosis from previous inflammation occurs (Fig. 2 ). The sequences that clearly depict these changes include the Short-Tau-Inversion-Recovery sequence or the T1-weighted fat-saturated post-Gadolinium sequence. The bone marrow edema (BME) lesions should be present on at least two consecutive slices or on one slice if there is more than one BME signal on that single slice. Along the spine, inflammatory changes at the corners of the vertebral bodies (three or more sites), spondylodiscitis, and fatty changes at the vertebral corners (Romanus lesions) are highly suggestive of axial SpA.
In recognition of the importance of sacroiliac joints MRI in the early diagnosis of SpA, positive MRI finding has been included as an important imaging criterion for the classification of axial SpA by ASAS (Assessment of SpondyloArthritis international Society) 44 (Fig. 3 ). ASAS comprises key opinion leaders, researchers and experts in the field of SpA and has worked on assessments of AS, measuring treatment response in clinical trials, re-evaluating existing classification criteria, and has developed new classification criteria for axial 44 and peripheral SpA 45 and golimumab [59] [60] [61] [62] . Approximately 60% of patients achieved the primary endpoint (ASAS20) with the active drug at week 14 or 24. ASAS 20 refers to the improvement criteria where patients achieved ≥20% or ≥1 unit improvement in at least three out of the four domains (patient global assessment, pain, function, and inflammation) with no ≥20% or ≥1 unit worsening in the remaining domain 63 . Generally, improvement with anti-TNF therapy occurs as soon as two weeks after the start of treatment with maximal benefit by week 12. Other benefits include improvement in healthrelated quality of life, fatigue, sleep disturbance, and absenteeism from work [64] [65] [66] .
In terms of adverse events, apart from a slight increase in risk of infection during the first year of treatment 67 and skin cancer 68 , anti-TNF therapy seems to have an acceptable safety profile. No definitive conclusions can be made so far regarding the risk of solid organ malignancy and lymphoproliferative disease as there has been conflicting data from different studies. Where lymphoma is concerned, the data is derived from usage of anti-TNF in rheumatoid arthritis (RA) 69 and unlike RA, AS is not known to be associated with lymphoma 70 . Larger studies need to be conducted before definitive conclusions can be drawn. Despite its good efficacy in the treatment of NSAID-refractory SpA, anti-TNF has not shown any retardation of radiographic spinal progression over a period of two years in clinical trials using infliximab, adalimumab, and etanercept [71] [72] [73] . This is in contrast to therapy with NSAIDs which has shown retardation of radiographic spinal progression in patients who are on continuous NSAIDs 74, 75 . Further research is required to determine the underlying mechanism of bone/syndesmophyte formation and whether treatment of early axial SpA patients would change the course of the disease.
Other therapies that may be potentially beneficial in AS include monthly intravenous pamidronate 76 injections and oral thalidomide 77 , but so far there have been no randomised controlled trials to definitively determine the efficacy of the therapies. Several biologic therapies that have proven efficacy in the treatment of other rheumatic diseases such as anakinra 78 , abatacept, 79 and tocilizumab 80 did not meet primary endpoints in AS clinical trials. Rituximab, a chimeric monoclonal antibody against CD20, has shown some efficacy for anti-TNF naïve patients [81] [82] [83] . A newer monoclonal antibody inhibiting IL-17A (Secukinumab), currently under phase 3 trial in SGH, looked promising with 61% of treatment group achieving ASAS 20 at six weeks compared to 17% in the placebo group 84 .
ROLE OF tHE SPONDYLOARtHRItIS CLINIC IN SGH
Given the rapid progress in the field of SpA in recent years, it is vital that a local centre take the lead in offering dedicated management of SpA with a focus on early diagnostics and advanced therapeutics in patients who fail conventional therapy. Specifically, this clinic aims to conduct clinical and scientific research, as well as to participate in drug trials. Since its inception in 2011, the SpA clinic to date has developed a registry of 150 patients fulfilling the ASAS criteria for SpA or the modified New York criteria for AS. Patients have the option of participating in our research and this involves completing surveys of their health and quality of life and donating samples of their blood, urine, or stool. Ongoing studies include studies to determine the factors that affect disease progression in the local population and the predictors for successful discontinuation of biologic therapy.
The SpA clinic also aims to provide education and training in SpA to rotating fellows and residents to increase their competency in the management of SpA. Fellows and residents are given handson opportunities to manage SpA patients in an adjoining room with the attending consultant, and to discuss management issues and treatment at the end of the consults. To reach out to more rheumatologists and trainees in the region, a workshop on SpA was conducted in October 2012 in conjunction with the Ten Topics Rheumatology Asia conference.
As patient education is the key to better understanding and compliance to treatment, the SpA clinic aims to provide counselling and education to our patients by our doctors or advanced practice nurse who specialises in this field. Anatomical models of the spine and joints and medical information in the form of pamphlets/ booklets have been effective in our education of SpA patients and will continue to be used to enhance their understanding.
SUMMARY
There has been remarkable progress in the understanding of SpA epidemiology, genetics, pathophysiology, and management in the recent 20 years and the achievements have significantly translated to better patient care and improved quality of life for patients affected by SpA. As more research is underway, we can expect greater discoveries in SpA in the future and the SpA clinic in SGH aims to be part of the global team contributing to the advancement of care and management of SpA, for the benefit of patients in Singapore and the region.
